A SOMATOSTATIN-secreting tumor derived from the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS). It is also found in the INTESTINE. Somatostatinomas are associated with DIABETES MELLITUS; CHOLELITHIASIS; STEATORRHEA; and HYPOCHLORHYDRIA. The majority of somatostatinomas have the potential for METASTASIS.
An almost always malignant GLUCAGON-secreting tumor derived from the PANCREATIC ALPHA CELLS. It is characterized by a distinctive migratory ERYTHEMA; WEIGHT LOSS; STOMATITIS; GLOSSITIS; DIABETES MELLITUS; hypoaminoacidemia; and normochromic normocytic ANEMIA.
A tumor that secretes VASOACTIVE INTESTINAL PEPTIDE, a neuropeptide that causes VASODILATION; relaxation of smooth muscles; watery DIARRHEA; HYPOKALEMIA; and HYPOCHLORHYDRIA. Vipomas, derived from the pancreatic ISLET CELLS, generally are malignant and can secrete other hormones. In most cases, Vipomas are located in the PANCREAS but can be found in extrapancreatic sites.
Tumors or cancer of the DUODENUM.
Tumors or cancer in the JEJUNUM region of the small intestine (INTESTINE, SMALL).
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Duodenal somatostatinoma and erythrocytosis in a patient with von Hippel-Lindau disease type 2A. (1/31)

A female with von Hippel-Lindau (VHL) disease type 2A first presented with erythrocytosis at the age of 9 years. This patient revealed multiple paragangliomas at age 22. After the removal of tumors, a retinal hemangioblastoma developed. Our diagnosis of VHL disease type 2A was confirmed. Moreover, systemic examination showed a duodenal somatostatinoma. Frequent and long-term monitoring is important for patients with pheochromocytomas or paragangliomas, and a screening for VHL disease and other hereditary cancer syndromes is recommended. Recognition of neuroendocrine tumors as a manifestation of VHL disease permits earlier diagnosis and improves prognosis.  (+info)

Large duodenal somatostatinoma in the third portion associated with severe glucose intolerance. (2/31)

A 51-year-old man was admitted with hyperglycemia and a duodenal tumor. Although his glycemic control was poor, basal C-peptide levels were not suppressed. Further examination revealed a mass measuring 7.8 cm in diameter in the third portion of the duodenum. Duodenectomy revealed a slow-growing sessile tumor located near Treitz's ligament. The immunohistochemical profile of sections of the specimen revealed the presence of somatostatin. The patient's serum somatostatin was elevated to 300 pg/ml preoperatively, but was reduced to 10 pg/ml postoperatively. Glycemic control also normalized after the operation.  (+info)

Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. (3/31)

Few studies have concerned the rare functioning endocrine pancreatic tumors associated with multiple endocrine neoplasia type 1 (MEN 1). When sporadic, these tumors have a poor prognosis. AIM: To analyze the frequency, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas and somatostatinomas recorded in the GTE (Groupe des Tumeurs Endocrines) registry. METHODS: Records of the patients whose GTE registry codes included glucagonoma, VIPoma or somatostatinoma were reviewed. The diagnosis was confirmed when there were clinical signs of a functioning tumor and/or when blood levels of the peptide were higher than twice the upper limit of normal. RESULTS: Among 580 patients with MEN 1, duodeno-pancreatic involvement was present in 307 (52.9%). Five (1.6%) had a glucagonoma, 3 (0.98%) a VIPoma and 2 (0.65%) a somatostatinoma. A clinical syndrome was present in 1 patient with glucagonoma, in the 3 with VIPomas and in 1 with somatostatinoma. Tumor size was greater than 3 cm more often for these rare tumours (67%) than in patients with other type of duodeno-pancreatic involvement (28%) (P=0.02) and visceral metastases were more frequent (40% vs 15%; P=0.056). Ten-year survival of patients with glucagonomas, VIPomas or somatostatinomas (53.8%; CI95%: 15.5-92.1) was poorer than that of patients with insulinomas (91.4%; CI95%: 83.399.5; P=0.01) or gastrinomas (81.7%; CI95%: 74.9-88.5; P=0.20) and close to that of patients with non-functioning tumors (62.2%, CI95%: 41.0-83.9; NS). CONCLUSION: Glucagonomas, VIPomas and somatostatinomas, especially the functioning type, are very rare in patients with MEN 1. Prognosis is poor, probably because of large tumor size and high rate of metastasis. Survival is similar to that in patients with non-functioning tumors.  (+info)

Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma. (4/31)

In somatostatinoma, a rare malignant somatostatin (SST)-secreting neoplasia, tumour regression is rarely observed, implying the need for novel antiproliferative strategies. Here, we characterized a long-term culture (SST-secreting cancer (SS-C cells)) established from a human somatostatinoma. High concentrations of SST and chromogranin A were released by SS-C cells and SST release was stimulated by depolarizing stimuli and inhibited by the SST analogue, octreotide. SS-C cells expressed mRNA for SST receptor (SSTR) subtypes 1, 2 and 4, being also able to bind native SST. Moreover, SS-C cells were positively stained with an antibody to SSTR2. SS-C cells also expressed interferon-gamma (IFN-gamma) receptor mRNA and measurable telomerase activity. Our findings indicate that in vitro exposure of SS-C cells to native SST-28, to octreotide, to IFN-gamma, or to 3'-azido-3'deoxythymidine (AZT), a telomerase inhibitor, results in inhibition of SS-C cell proliferation. Concomitant with growth inhibition, apoptosis was detected in SST-, octreotide-, IFN-gamma- or AZT-treated SS-C cell cultures. Taken together our results characterized native SST, SST analogues, IFN-gamma and a telomerase inhibitor as growth-inhibiting and proapoptotic stimuli in cultured human somatostatinoma cells. Based on these findings, the potential of SST analogues, IFN-gamma and AZT, alone or in combination, should be further explored in the medical treatment of somatostatinoma.  (+info)

Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. (5/31)

Pancreatic endocrine tumours (PETs) are rare and 'indolent' neoplasms that usually develop metastatic lesions and exhibit poor response to standard medical treatments. Few studies have investigated pathways responsible for PET cell growth and invasion and no alternative therapeutic strategies have been proposed. In a recent microarray analysis for genes up-regulated in PETs, we have described the up-regulation of soluble Src family tyrosine kinases in this neoplasia, which may represent potentially promising candidates for therapy. Herein, we have investigated the expression and function of Src family kinases in PETS and PET cell lines. Western blot analysis indicated that Src is highly abundant in the PET cell lines CM and QGP-1. Immunohistochemistry and Western blot analyses showed that Src is up-regulated also in human PET lesions. Pharmacological inhibition of Src family kinases by the specific inhibitor PP2 strongly interfered with adhesion, spreading and migration of PET cell lines. Accordingly, the actin cytoskeleton was profoundly altered after inhibition of Src kinases, whereas even prolonged incubation with PP2 exerted no effect on cell cycle progression and/or apoptosis of PET cells. A transient increase in tyrosine phosphorylation of a subset of proteins was observed in QGP-1 cells adhering to the plate, with a peak at 75 min after seeding, when approximately 80% of cells were attached. Inhibition of Src kinases caused a dramatic reduction in the phosphorylation of proteins with different molecular weight that were isolated from the cell extracts by anti-phosphotyrosine immunoprecipitation or pull-down with the SH2 domain of Src. Among them, the docking protein p130Cas interacted with Src and is a major substrate of the Src kinases in QGP-1 cells undergoing adhesion. Our results suggest that Src kinases play a specific role during adhesion, spreading and migration of PET cells and may indicate therapeutical approaches directed to limiting the metastatic potential of these cells.  (+info)

Ampullary somatostatinomas and jejunal gastrointestinal stromal tumor in a patient with Von Recklinghausen's disease. (6/31)

Von Recklinghausen's disease is an autosomal dominant hereditary disease associated with a wide number of neoplasms. We report a case of a 47-year-old Caucasian male affected by Von Recklinghausen's disease who developed a malignant somatostatinoma of the papilla major and minor associated with jejunal gastrointestinal stromal tumour with uncertain behaviour. At laparotomy, multiple hepatic metastases were evident. Whipple pancreaticoduodenectomy, jejunal resection, extensive lymphadenectomy and multiple hepatic wedge resections were performed. The patient was alive without recurrence after 24 mo. This is the fourth case reported in the world literature of a patient with Von Recklinghausen's disease associated with periampullary somatostatinomas and jejunal stromal tumor. In patients with Von Recklinghausen's disease who complain of gastrointestinal symptoms, a high suspicion index for periampullary endocrine tumours and/or gastrointestinal stromal tumour is required. An aggressive surgical approach seems to give long term survival also in metastatic patients.  (+info)

Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. (7/31)

 (+info)

Large somatostatin-producing endocrine carcinoma of the ampulla of vater in association with GIST in a patient with von Recklinghausen's disease. Case report and review of the literature. (8/31)

CONTEXT: Somatostatin-producing endocrine tumors of the duodenum are very rare neoplasms of the gastrointestinal tract. These tumors may be associated with von Recklinghausen's disease. CASE REPORT: We present the case of a 49-year-old female patient with von Recklinghausen's disease and an incidentally diagnosed ampullary neoplasm. The patient was treated with a classical pancreaticoduodenectomy. At surgery, a mass was found in the greater curve of the stomach which was resected using the classic Whipple procedure. Histology and immunohistochemistry showed that the duodenal tumor was an ampullary somatostatin-producing endocrine carcinoma while the gastric tumor was a gastrointestinal stromal tumor (GIST). The postoperative course was uneventful and the patient is alive, without tumor recurrence, six years after surgery. CONCLUSION: Somatostatin-producing endocrine tumors of the duodenum are rare tumors, often associated with von Recklinghausen's disease; these neoplasms should be treated aggressively using radical surgical resection. Although local resection may be appropriate for small duodenal somatostatin-producing tumors, a pancreaticoduodenectomy is usually required for larger tumors.  (+info)

Somatostatinoma is a rare type of neuroendocrine tumor that originates from the delta cells (D cells) of the diffuse endocrine system, which are responsible for producing and secreting somatostatin, a hormone that inhibits the release of several other hormones. These tumors can occur in various organs, but they most commonly arise in the pancreas and the small intestine (duodenum).

Somatostatinomas are typically slow-growing and can be functional or nonfunctional. Functional somatostatinomas actively produce and secrete excessive amounts of somatostatin, which can lead to a variety of clinical symptoms due to the inhibition of other hormones' functions. Nonfunctional somatostatinomas do not secrete significant amounts of somatostatin and are often discovered incidentally during imaging studies or when they cause local mass effects.

Common symptoms associated with functional somatostatinomas include diarrhea, abdominal pain, weight loss, fat malabsorption, and steatorrhea (fatty stools). They can also lead to diabetes mellitus due to the inhibition of insulin secretion. Additionally, these tumors may cause symptoms related to hormone deficiencies or the compression of nearby structures, depending on their location.

Diagnosis typically involves imaging studies such as CT scans, MRI, and PET scans, along with biochemical tests to measure somatostatin levels in the blood. A definitive diagnosis usually requires a tissue biopsy or surgical removal of the tumor for histopathological examination. Treatment options include surgery, chemotherapy, radiation therapy, and targeted therapies, depending on the stage and location of the tumor.

A glucagonoma is a rare type of neuroendocrine tumor that originates from the alpha cells of the pancreas, where the hormone glucagon is produced. This tumor can lead to an overproduction of glucagon, resulting in a characteristic syndrome known as the "glucagonoma syndrome."

The symptoms of glucagonoma syndrome may include:

1. A distinctive rash called necrolytic migratory erythema, which is characterized by red, swollen, and painful skin lesions that can affect various parts of the body.
2. Weight loss
3. Diabetes or high blood sugar levels (hyperglycemia)
4. Anemia
5. Deep vein thrombosis (blood clots in the deep veins)
6. Depression and confusion
7. A decreased appetite
8. Fatigue and weakness
9. Diarrhea or steatorrhea (fatty stools)
10. High levels of amino acids, fatty acids, and zinc in the blood.

Glucagonomas are typically slow-growing tumors, but they can metastasize (spread) to other organs such as the liver, lymph nodes, and bones. Treatment options for glucagonoma may include surgery to remove the tumor, chemotherapy, targeted therapy, or radiation therapy. Regular follow-up care is essential to monitor the tumor's progression and manage any associated symptoms.

A vipoma, also known as a verner morrison syndrome or a non-insulin-secreting pancreatic tumor, is a rare medical condition characterized by the excessive production and secretion of vasoactive intestinal peptides (VIP) from a functional neuroendocrine tumor in the pancreas. This leads to a series of symptoms known as watery diarrhea, hypokalemia, and acidosis (WDHA) syndrome due to the effects of VIP on the gastrointestinal system. Symptoms include severe watery diarrhea, dehydration, electrolyte imbalances, and low blood pressure. Treatment typically involves surgical removal of the tumor, along with supportive care to manage symptoms and correct electrolyte abnormalities.

Duodenal neoplasms refer to abnormal growths in the duodenum, which is the first part of the small intestine that receives digestive secretions from the pancreas and bile duct. These growths can be benign or malignant (cancerous).

Benign neoplasms include adenomas, leiomyomas, lipomas, and hamartomas. They are usually slow-growing and do not spread to other parts of the body. However, they may cause symptoms such as abdominal pain, bleeding, or obstruction of the intestine.

Malignant neoplasms include adenocarcinomas, neuroendocrine tumors (carcinoids), lymphomas, and sarcomas. They are more aggressive and can invade surrounding tissues and spread to other parts of the body. Symptoms may include abdominal pain, weight loss, jaundice, anemia, or bowel obstruction.

The diagnosis of duodenal neoplasms is usually made through imaging tests such as CT scans, MRI, or endoscopy with biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these modalities.

Jejunal neoplasms refer to abnormal growths or tumors in the jejunum, which is the middle section of the small intestine. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant jejunal neoplasms are often aggressive and can spread to other parts of the body, making them potentially life-threatening.

There are several types of jejunal neoplasms, including:

1. Adenocarcinomas: These are cancerous tumors that develop from the glandular cells lining the jejunum. They are the most common type of jejunal neoplasm.
2. Carcinoid tumors: These are slow-growing neuroendocrine tumors that arise from the hormone-producing cells in the jejunum. While they are usually benign, some can become malignant and spread to other parts of the body.
3. Gastrointestinal stromal tumors (GISTs): These are rare tumors that develop from the connective tissue cells in the jejunum. They can be benign or malignant.
4. Lymphomas: These are cancerous tumors that develop from the immune system cells in the jejunum. They are less common than adenocarcinomas but can be aggressive and spread to other parts of the body.
5. Sarcomas: These are rare cancerous tumors that develop from the connective tissue cells in the jejunum. They can be aggressive and spread to other parts of the body.

Symptoms of jejunal neoplasms may include abdominal pain, bloating, diarrhea, weight loss, and bleeding in the stool. Treatment options depend on the type and stage of the neoplasm but may include surgery, chemotherapy, radiation therapy, or a combination of these approaches.

Somatostatin is a hormone that inhibits the release of several hormones and also has a role in slowing down digestion. It is produced by the body in various parts of the body, including the hypothalamus (a part of the brain), the pancreas, and the gastrointestinal tract.

Somatostatin exists in two forms: somatostatin-14 and somatostatin-28, which differ in their length. Somatostatin-14 is the predominant form found in the brain, while somatostatin-28 is the major form found in the gastrointestinal tract.

Somatostatin has a wide range of effects on various physiological processes, including:

* Inhibiting the release of several hormones such as growth hormone, insulin, glucagon, and gastrin
* Slowing down digestion by inhibiting the release of digestive enzymes from the pancreas and reducing blood flow to the gastrointestinal tract
* Regulating neurotransmission in the brain

Somatostatin is used clinically as a diagnostic tool for detecting certain types of tumors that overproduce growth hormone or other hormones, and it is also used as a treatment for some conditions such as acromegaly (a condition characterized by excessive growth hormone production) and gastrointestinal disorders.

Octreotide is a synthetic analogue of the natural hormone somatostatin, which is used in medical treatment. It is a octapeptide with similar effects to somatostatin, but with a longer duration of action. Octreotide is primarily used in the management of acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and diarrhea and flushing associated with carcinoid syndrome.

It works by inhibiting the release of several hormones, including growth hormone, insulin, glucagon, and gastrin. This results in a decrease in symptoms caused by excessive hormone secretion, such as reduced growth hormone levels in acromegaly, decreased tumor size in some GEP-NETs, and improved diarrhea and flushing in carcinoid syndrome.

Octreotide is available in several forms, including short-acting subcutaneous injections (Sandostatin®), long-acting depot intramuscular injections (Sandostatin LAR®), and a slow-release formulation for the treatment of diarrhea associated with AIDS (Mycapssa™).

The medical definition of Octreotide is:

A synthetic octapeptide analogue of somatostatin, used in the management of acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and diarrhea and flushing associated with carcinoid syndrome. Octreotide inhibits the release of several hormones, including growth hormone, insulin, glucagon, and gastrin, leading to symptomatic improvement in these conditions. It is available as short-acting subcutaneous injections, long-acting depot intramuscular injections, and a slow-release formulation for diarrhea associated with AIDS.

Somatostatin receptors (SSTRs) are a group of G protein-coupled receptors that bind to the neuropeptide hormone somatostatin. There are five subtypes of SSTRs, named SSTR1 through SSTR5, each with distinct physiological roles and tissue distributions.

Somatostatin is a small peptide that is widely distributed throughout the body, including in the central nervous system, gastrointestinal tract, pancreas, and other endocrine organs. It has multiple functions, including inhibition of hormone release, regulation of cell proliferation, and modulation of neurotransmission.

SSTRs are expressed on the surface of many different types of cells, including neurons, endocrine cells, and immune cells. They play important roles in regulating various physiological processes, such as inhibiting the release of hormones like insulin, glucagon, and growth hormone. SSTRs have also been implicated in a number of pathophysiological conditions, including cancer, neurodegenerative diseases, and inflammatory disorders.

In recent years, SSTRs have become an important target for the development of new therapeutic strategies, particularly in the treatment of neuroendocrine tumors (NETs). Several radiolabeled somatostatin analogues have been developed that can selectively bind to SSTRs on NET cells and deliver targeted radiation therapy. These agents have shown promising results in clinical trials and are now being used as standard of care for patients with advanced NETs.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

6. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other ... de Herder, Wouter W.; Zandee, Wouter T.; Hofland, Johannes (2000). Feingold, KR; Anawalt, B; Boyce, A (eds.). Somatostatinoma. ...
May 2013). "New syndrome of paraganglioma and somatostatinoma associated with polycythemia". Journal of Clinical Oncology. 31 ( ... Polycythemia Duodenal somatostatinoma Retinal and choroidal vascular changes Paraganglioma/Pheochromocytoma Pheochromocytoma ...
A tumor of the delta cells is called a "somatostatinoma". When a person is infected with H. pylori the lower region of the ...
Pacak K, Jochmanova I, Prodanov T, et al: New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J ... The most common therapies for secondary polycythemia are phlebotomies and, for paraganglioma and/or somatostatinoma in this ... Ocular Manifestations of Hypoxia-Inducible Factor-2A Paranglioma-Somatostatinoma-Polycythemia Syndrome. J Opthal 2014. DOI: ...
... somatostatinoma MeSH C04.557.465.625.650.240.847 - vipoma MeSH C04.557.465.625.650.510 - melanoma MeSH C04.557.465.625.650.510. ... somatostatinoma MeSH C04.557.470.200.025.370.847 - vipoma MeSH C04.557.470.200.025.390 - carcinoma, renal cell MeSH C04.557. ... somatostatinoma MeSH C04.588.274.761.500.750 - vipoma MeSH C04.588.274.761.750 - carcinoma, pancreatic ductal MeSH C04.588. ... somatostatinoma MeSH C04.588.322.421.500.750 - vipoma MeSH C04.588.322.421.750 - carcinoma, pancreatic ductal MeSH C04.588. ...
Smith-Magenis syndrome Snapping hip syndrome Snapping scapula syndrome Sneddon's syndrome Solipsism syndrome somatostatinoma ...
... somatostatinoma MeSH C19.344.421.500.750 - vipoma MeSH C19.344.421.750 - carcinoma, pancreatic ductal MeSH C19.344.609.145 - ...
... somatostatinoma MeSH C06.301.761.500.750 - vipoma MeSH C06.301.761.750 - carcinoma, pancreatic ductal MeSH C06.405.117.102 - ... somatostatinoma MeSH C06.689.667.500.750 - vipoma MeSH C06.689.667.625 - carcinoma, pancreatic ductal MeSH C06.689.750.650 - ...
... malignant M8156/1 Somatostatinoma, NOS Somatostatin cell tumor, NOS M8156/3 Somatostatinoma, malignant somatostatin cell tumor ...
... somatostatinoma: these rare tumors are associated with elevated blood glucose levels, achlorhydria, cholelithiasis, and ...
... in the central nervous system Peritoneal and Pleural Mesothelioma Somatostatinoma (pancreas) Prolactinoma of the pituitary ...
... syndrome Sneddon's syndrome Sociophobia Soft-tissue sarcoma Sohval-Soffer syndrome Somatization disorder Somatostatinoma Sommer ...
6. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other ... de Herder, Wouter W.; Zandee, Wouter T.; Hofland, Johannes (2000). Feingold, KR; Anawalt, B; Boyce, A (eds.). Somatostatinoma. ...
We present a patient with somatostatinoma in which an immunocytochemical study of the specimens from pancreas and liver showed ... Like any other pancreatic islet cell carcinoma, a somatostatinoma may also produce several different hormones such as ... Cardinal manifestations of a somatostatinoma include gallstones, mild diabetes mellitus, steatorrhoea, diarrhoea and dyspepsia ... Somatostatinoma is one of the rarest tumours of the endocrine pancreas. ...
Somatostatinoma. Extremely rare NET that usually occurs in the pancreas or parts of the small bowel and may produce extra ...
Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas. Hepatogastroenterology. 2008 Jul-Aug. 55(85): ...
Learn about Pancreatic Neuroendocrine Neoplasms (pNENs), including symptoms, causes, and treatments. If you or a loved one is affected by this condition,
Somatostatinoma. *PPoma. *Non-functioning NET of the pancreas. *GI Neuroendocrine Tumors *Gastric Carcinoids Type I, II and III ...
Somatostatinoma:. *Diarrhea. *Gallstones. *Yellowing of the skin or eyes. *Unexplained weight loss ...
Economopoulos P, Christopoulos C. Somatostatinoma syndrome. Ann Gastroenterol. 2001;14:252-260. ... Economopoulos P, Christopoulos C. Somatostatinoma syndrome. Ann Gastroenterol. 2001;14:252-260. ... Economopoulos P, Christopoulos C. Somatostatinoma syndrome. Ann Gastroenterol. 2001;14:252-260. ... Pancreatic somatostatinoma: presentation with recurrent episodes of severe hyperglycemia and ketoacidosis. Q J Med. 1988;68:559 ...
Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas. Hepatogastroenterology. 2008 Jul-Aug. 55(85): ...
The best Clinical Endocrinology source in the world, and FREE ...
Most common location for gastrinoma and somatostatinoma Pancreatic head * Most common islet cell tumor of pancreas ...
somatostatinoma. *vasoactive intestinal peptide releasing tumour (VIPoma). Reference:. *(1) Bond-Smith G et al. Pancreatic ...
What is Somatostatinoma, Know its Causes, Symptoms, Treatment, Diagnosis. Pramod Kerkar, M.D., FFARCSI, DA - ...
Phenotype data for mouse gene Sepsecs. Discover Sepsecss significant phenotypes, expression, images, histopathology and more. Data for gene Sepsecs is all freely available for download.
What are the findings in a somatostatinoma? A somatostatinoma is a somatostatin-secreting tumor. Somatostatin suppresses the ...
somatostatinoma cell line:QGP-1.CNhs11869.10781-110G7. 0.00. spinal cord - adult, donor10196.CNhs13807.10181-103D1. 0.00. ...
somatostatinoma cell line:QGP-1.CNhs11869.10781-110G7. 0.00. spinal cord - adult, donor10196.CNhs13807.10181-103D1. 0.00. ...
Overview of Pancreatic Endocrine Tumors - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - Medical Professional Version.
Somatostatinoma. Thyroid/parathyroid tumors that stain positive for chromogranin A are as follows:. * Medullary thyroid cancer ...
Somatostatinoma (morphologic abnormality). Code System Preferred Concept Name. Somatostatinoma (morphologic abnormality). ...
Several distinct disorders of glucose tolerance exist. The most widely used classification of diabetes mellitus (DM) and allied categories of glucose intolerance is that recommended by the World Health Organization (WHO) in 1985.
Somatostatinoma Whats New Last Posted: Mar 01, 2023 * Functional significance of germline EPAS1 variants. Dwight Trisha, et al ...
Label: duodenal somatostatinoma Synonyms: duodenal somatostatinoma Alternative IDs: als API: GO SPARQL: GO ...
Somatostatinoma. Tumor of pancreatic δ cells. Overproduction of somatostatin. Decreased secretion of secretin, cholecystokinin ...
δ-cells → Somatostatinoma → ↑↑ Somatostatin: *↑↑ Somatostatin → ↓↓ Insulin → Diabetes mellitus. *↑↑ Somatostatin → ↓↓ Gastrin ... δ-cells → Somatostatinoma → ↑↑ Somatostatin. *↑↑ Somatostatin → ↓↓ Insulin → Diabetes mellitus. *↑↑ Somatostatin → ↓↓ Gastrin ...
Words ending in -ma. Full list of words with these elements: drama, cinema, emma, dilemma, plasma, diploma, asthma...
Somatostatinoma.. *Systemic mastocytosis.. *Addisons disease.. Learn more HERE and HERE.. D- Less common intestinal diseases. ...
DIABETES MELLITUS - General Characteristics, Pancreas, Classification, Etiopathogenesis, Pathological Changes, Clinical Features, Diagnosis and Treatment
Management of Somatostatinoma.- Management of VIPoma.- Congenital Diaphragmatic Hernia.- Tracheoesophageal Fistula.- Other ...
  • The tumors are named based on the hormone it produces such as glucagonoma, insulinoma, gastrinoma, and somatostatinoma. (vumc.org)
  • La secreción hormonal depende del tipo de CÉLULAS DE LOS ISLOTES presentes en los tumores: GLUCAGÓN de las CÉLULAS PANCREÁTICAS ALFA, INSULINA de las CÉLULAS PANCREÁTICAS BETA y SOMATOSTATINA de las CÉLULAS D. La mayoría son malignos exceptuando a los tumres productores de insulina (INSULINOMA). (bvsalud.org)
  • 6. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. (wikipedia.org)
  • A somatostatinoma is a somatostatin-secreting tumor. (rahulgladwin.com)
  • BACKGROUND AND AIMS: Somatostatinoma of the ampulla of Vater (SAV) is a rare neuroendocrine tumor that usually appears with atypical clinical manifestations and is associated with Von Recklinghausen's disease. (bvsalud.org)
  • We present a patient with somatostatinoma in which an immunocytochemical study of the specimens from pancreas and liver showed a weak positive reaction for gastrin besides a strong positive reaction for somatostatin. (bioseek.eu)
  • Cardinal manifestations of a somatostatinoma include gallstones, mild diabetes mellitus, steatorrhoea, diarrhoea and dyspepsia. (bioseek.eu)
  • Somatostatinoma is one of the rarest tumours of the endocrine pancreas. (bioseek.eu)
  • Carcinoid syndrome due to a malignant somatostatinoma. (bioseek.eu)
  • Pipeleers D, Couturier E, Gepts W, Reynders J, Somers G. Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia. (bioseek.eu)
  • Usually it involves the non-insulin-producing cell types, the pancreatic alpha cells and the pancreatic delta cells (somatostatin-secreting cells) in glucagonoma and somatostatinoma, respectively. (icd10data.com)
  • 4. Somatostatin-secreting islet cell tumor (somatostatinoma): suppression of growth hormone (GH) release induced by GH-releasing hormone. (nih.gov)
  • La secreción hormonal depende del tipo de CÉLULAS DE LOS ISLOTES presentes en los tumores: GLUCAGÓN de las CÉLULAS PANCREÁTICAS ALFA, INSULINA de las CÉLULAS PANCREÁTICAS BETA y SOMATOSTATINA de las CÉLULAS D. La mayoría son malignos exceptuando a los tumres productores de insulina (INSULINOMA). (bvsalud.org)
  • Somatostatinoma is a pancreatic neuroendocrine tumor (PanNET) that originates from delta cells. (picmonic.com)
  • Somatostatinoma is a functional pancreatic neuroendocrine tumor (PanNET). (picmonic.com)
  • One patient also had a rare tumor of the duodenum known as a somatostatinoma . (nih.gov)
  • 9. A case of duodenal somatostatinoma: diagnostic usefulness of calcium--pentagastrin test. (nih.gov)
  • 10. Comparative diagnostic value of the calcium-pentagastrin test versus the tolbutamide test in a patient with a somatostatinoma. (nih.gov)
  • Johns Hopkins Guides , www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547136/all/Somatostatinoma. (hopkinsguides.com)
  • Chemotherapy can be considered in somatostatinoma patients. (picmonic.com)
  • 2. Pancreatic somatostatinoma: a case report and review of the literature. (nih.gov)
  • 12. Somatostatinoma: clinico-pathological features of three cases and literature reviewed. (nih.gov)